Bifogade filer
Relheart’s CEO Presents the Company and Current Share Issue – Recording Now Available
Kurs
+0,36%
Likviditet
0,11 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-05-28 | N/A | Årsstämma |
| 2026-02-19 | 08:30 | Bokslutskommuniké 2025 |
| 2025-12-16 | - | Extra Bolagsstämma 2025 |
| 2025-08-28 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-12 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2025-06-11 | - | Årsstämma |
| 2025-05-15 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Split HEART 100:1 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-11-05 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-10 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2024-06-07 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-24 | - | Extra Bolagsstämma 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-16 | - | Årsstämma |
| 2023-06-15 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2023-06-14 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-15 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2022-06-14 | - | Årsstämma |
| 2022-05-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-08-05 | - | Extra Bolagsstämma 2021 |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-03 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-08-04 | - | Extra Bolagsstämma 2020 |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-19 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2020-05-18 | - | Årsstämma |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-27 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2019-03-26 | - | Årsstämma |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-11 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-27 | - | Extra Bolagsstämma 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-31 | - | Kvartalsrapport 2017-Q1 |
| 2017-05-11 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2017-05-10 | - | Årsstämma |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-11-24 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-11 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-10 | - | Årsstämma |
| 2016-04-20 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-12 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-26 | - | Kvartalsrapport 2015-Q1 |
| 2015-05-21 | - | X-dag ordinarie utdelning HEART 0.00 SEK |
| 2015-05-20 | - | Årsstämma |
| 2015-02-18 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Scandinavian Real Heart AB (publ) announces today, January 14, 2026, that a recording of CEO Ina Laura's company presentation, held in connection with the extraordinary general meeting on December 16, 2025, is now available on the company's YouTube channel.
In the presentation, CEO Ina Laura Perkins gives an overview of the company's operations, technology platform, and strategic direction going forward. Parts of the presentation also touch on the rights issue that the company has previously communicated, the subscription period for which began yesterday, January 13, 2026. The rights issue closes on January 27.
Ina Laura also demonstrates today's existing artificial heart systems and highlights their limitations from a patient perspective. She compares these with Realheart's patient-centered solution—a heart designed to mimic the natural blood flow of the human heart and an external patient unit that is quiet, lightweight, and has a long battery life. All this is done to create the best conditions for long-term treatment of patients with severe heart failure.
As previously announced, the purpose of the issue is to finance the continued development of Realheart's artificial heart Realheart® TAH and to strengthen the company's financial position ahead of upcoming development and regulatory steps. Full terms and conditions for the issue, including the subscription period, use of issue proceeds, and other details, are set out in previous press releases.
Read more and subscribe here: https://realheart.se/preferential-rights-issue-realheart/
A recording of the presentation* is available on the Company's YouTube channel: https://youtu.be/AaaZkgmn4GM
* The presentation is in Swedish.
For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se
About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se